UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014134
Receipt number R000015841
Scientific Title The effect of tolvaptan on renal function during intensive treatment in patients with congestive heart failure
Date of disclosure of the study information 2014/05/31
Last modified on 2014/11/04 21:20:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of tolvaptan on renal function during intensive treatment in patients with congestive heart failure

Acronym

Renoprotective effect of tolvaptan in acute phase of patients with congestive heart failure

Scientific Title

The effect of tolvaptan on renal function during intensive treatment in patients with congestive heart failure

Scientific Title:Acronym

Renoprotective effect of tolvaptan in acute phase of patients with congestive heart failure

Region

Japan


Condition

Condition

congestive heart failure

Classification by specialty

Cardiology Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the effect on renal function, hemodynamics and neurohumoral factors in acute phase of HF patients between tolvaptan and furosemide.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

renal function

Key secondary outcomes

1. daily urine volume, fluid balance
2. plasma renin activity, plasma aldosterone concentration, catecholamines, BNP
3. systemic blood pressure
4. electrolytes
5. cardio-thoracic ratio
6. durations of NIPPV use, CCU and total hospitalization
7. in-hospital and long-term mortality


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

(Standard treatment group)
Daily 40 mg of intravenous furosemide (20 mg x 2), in addition to intravenous 0.025 gamma of carperitide and 200 mg of canrenoate potassium for 5 days. Renal functions and neurohumoral factors were evaluated on day 6 after the admission.

Interventions/Control_2

(Tolvaptan treatment group)
Daily 7.5 mg of oral Tolvaptan administration (7.5 mg x 1), in addition to intravenous 0.025 gamma of carperitide and 200 mg of canrenoate potassium for 5 days. Renal functions and neurohumoral factors were evaluated on day 6 after the admission.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patient urgently hospitalized due to acute heart failure syndrome, or worsened chronic heart failure, with informed consent.

Key exclusion criteria

(i) Patient with malignant neoplasm who is expected that life expectancy is within 6 months
(ii) Maintenance dialysis patient
(iii) Patient with shock or pre shock vital signs on admission
(iv) Patient younger than 30 years old
(v) Inadequate patient judged by principal investigator

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kentaro Jujo

Organization

Nishiarai Heart Center Hospital

Division name

Department of Cardiology

Zip code


Address

1-12-8, Nishiarai Honcho, Adachi-ku, Tokyo, Japan

TEL

+81358380730

Email

juken1123@hotmail.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kentaro Jujo

Organization

Nishiarai Heart Center Hospital

Division name

Department of Cardiology

Zip code


Address

1-12-8, Nishiarai Honcho, Adachi-ku, Tokyo, Japan

TEL

+81358380730

Homepage URL


Email

juken1123@hotmail.co.jp


Sponsor or person

Institute

Nishiarai Heart Center Hospital

Institute

Department

Personal name



Funding Source

Organization

Nishiarai Heart Center Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

西新井ハートセンター病院


Other administrative information

Date of disclosure of the study information

2014 Year 05 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 12 Month 01 Day

Date of IRB


Anticipated trial start date

2013 Year 01 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 05 Month 31 Day

Last modified on

2014 Year 11 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015841


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name